Richard Nolan Townsend - Jan 5, 2024 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Executive Officer, Director
Signature
/s/ Jenny Robertson, Attorney-in-Fact
Stock symbol
LXEO
Transactions as of
Jan 5, 2024
Transactions value $
$0
Form type
4
Date filed
1/9/2024, 06:52 PM
Previous filing
Nov 2, 2023
Next filing
May 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXEO Common Stock Award $0 +43.8K +34.46% $0.00 171K Jan 5, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXEO Stock Option (Right to Buy) Award $0 +263K $0.00 263K Jan 5, 2024 Common Stock 263K $14.48 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2025, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
F2 Total represents 126,945 shares of Common Stock and 43,750 RSUs.
F3 25% of the shares underlying the option shall vest on January 5, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.